ADEPT

A single arm phase II study of ADjuvant Endocrine therapy, subcutaneous Pertuzumab, and Trastuzumab fixed-dose combination for patients with anatomic stage I hormone receptor positive, HER2-positive breast cancer -- NCT04569747

Objective

 This clinical trial aims to evaluate invasive disease-free survival when treated with a "de-escalated" regimen of hormonal and dual HER2-targeted therapy, with omission of chemotherapy. Objective is to evaluate 3-year invasive disease-free survival in patients with stage I HR+ HER2+ breast cancer treated with adjuvant HP plus endocrine therapy.

Principal Investigator(s)

Edward Wyluda, DO

Clinical Trial Categories

• Treatment
• Breast Cancer

Contact

Meghan Stone, BHS at 508-862-7284
or mestone@capecodhealth.org

How to Participate

Contact your oncologist, oncology nurse or the Oncology Research Program Manager.